PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Types • Cause • Management • Epidemiology • Economic burden • PART 06: Pipeline analysis • Semprana • Rizaport • Sumatriptan • DFN-11 • Lasmiditan • SUD001 • AMG 334 • DFN-02 PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by type of treatment • Preventative • Abortive PART 09: Market segmentation by therapeutic class • Triptans • Ergot alkaloids • Other PART 10: Geographical segmentation • Global migraine drugs market by geographical segmentation 2015-2020 • Migraine drugs market in Americas • Migraine drugs market in EMEA • Migraine drugs market in APAC PART 11: Market drivers • Growing awareness about migraine and its treatment options • Tentative approval of pipeline candidates • High unmet needs • Increased prevalence of migraines PART 12: Impact of drivers PART 13: Market challenges • Lack of proper diagnosis • Adverse effects of drugs • Increased preference for alternative therapies • Generic penetration PART 14: Impact of drivers and challenges PART 15: Market trends • Antimigraine devices and headbands • Increase in R&D • Novel product innovations • Strategic alliances PART 16: Vendor landscape • Competitive scenario • Allergan • Endo International • GlaxoSmithKline • Impax • Pfizer • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Percentage of migraine sufferers worldwide by gender Exhibit 03: Global migraine drugs market: Pipeline portfolio Exhibit 04: Global migraine drugs market 2015-2020 ($ billions) Exhibit 05: Five forces analysis Exhibit 06: Preventative medications based on efficacy of drugs Exhibit 07: Medications used based on severity of migraines Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015 Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015 Exhibit 10: Market share of triptans by ROA 2015 Exhibit 11: Global migraine drugs market by geography 2015 Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions) Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions) Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions) Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions) Exhibit 16: Impact of drivers Exhibit 17: Percentage of population diagnosed with migraine in US 2014 Exhibit 18: Impact of drivers and challenges Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions) Exhibit 20: Allergan: Key takeaways Exhibit 21: Endo International: Key takeaways Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions) Exhibit 23: GlaxoSmithKline: Key takeaways Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions) Exhibit 25: Impax: Key takeaways Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions) Exhibit 27: Pfizer: Key takeaways

Allergan, Endo International, GlaxoSmithKline, Impax, Pfizer, Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, Zogenix.